{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:25:57Z","timestamp":1790641557340,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"7-8","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.bulcan.2022.08.014","type":"journal-article","created":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T23:15:33Z","timestamp":1665270933000},"page":"748-753","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Acute kidney injury after CAR-T cell infusion"],"prefix":"10.1016","volume":"111","author":[{"given":"Adrien","family":"Rousseau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Zafrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.bulcan.2022.08.014_bib0255","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.bulcan.2022.08.014_bib0260","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.bulcan.2022.08.014_bib0265","first-page":"515","article-title":"Chimeric antigen receptor-t cells for targeting solid tumors: current challenges and existing strategies","volume":"33","author":"Springuel","year":"2019","journal-title":"BioDrugs Clin Immunother Biopharm Gene Ther"},{"key":"10.1016\/j.bulcan.2022.08.014_bib0270","unstructured":"Rousseau A, Gougis P. Les CAR-T cells \u00e0 l\u2019\u00e9preuve de l\u2019oncologie solide. Innov Th\u00e9rapeutiques En Oncol [Internet]. 1 nov 2015 [cit\u00e9 10 oct 2020];1(1). Disponible sur: http:\/\/www.jle.com\/fr\/revues\/ito\/e-docs\/les_car_t_cells_a_lepreuve_de_loncologie_solide_318620\/article.phtml?tab=texte."},{"issue":"2","key":"10.1016\/j.bulcan.2022.08.014_bib0275","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41571-020-0427-6","article-title":"CAR T cell therapies for patients with multiple myeloma","volume":"18","author":"Mikkilineni","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"23","key":"10.1016\/j.bulcan.2022.08.014_bib0280","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine Storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.bulcan.2022.08.014_bib0285","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1097\/CCM.0000000000002053","article-title":"Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia","volume":"45","author":"Fitzgerald","year":"2017","journal-title":"Crit Care Med"},{"issue":"8","key":"10.1016\/j.bulcan.2022.08.014_bib0290","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.bulcan.2022.08.014_bib0295","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.bulcan.2022.08.014_bib0300","first-page":"1","article-title":"Kidney disease: Improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury","volume":"2","author":"Kellum","year":"2012","journal-title":"Kidney Int Suppl"},{"issue":"5","key":"10.1016\/j.bulcan.2022.08.014_bib0305","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.ekir.2021.02.013","article-title":"Systematic review of risk factors and incidence of acute kidney injury among patients treated with CAR-T cell therapies","volume":"6","author":"Kanduri","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"3, Supplement","key":"10.1016\/j.bulcan.2022.08.014_bib0310","doi-asserted-by":"crossref","first-page":"S168","DOI":"10.1016\/j.bbmt.2018.12.307","article-title":"Acute kidney injury after chimeric antigen receptor T-cell therapy for pediatric acute lymphoblastic leukemia","volume":"25","author":"Myers","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.bulcan.2022.08.014_bib0315","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1182\/asheducation-2016.1.567","article-title":"Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia","volume":"2016","author":"Frey","year":"2016","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"6","key":"10.1016\/j.bulcan.2022.08.014_bib0320","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1053\/j.ajkd.2020.08.017","article-title":"Acute Kidney Injury After the CAR-T Therapy Tisagenlecleucel","volume":"77","author":"Lee","year":"2021","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1016\/j.bulcan.2022.08.014_bib0325","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.bbmt.2020.02.012","article-title":"Acute kidney injury after CAR-T cell therapy: low incidence and rapid recovery","volume":"26","author":"Gutgarts","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.bulcan.2022.08.014_bib0330","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1053\/j.ajkd.2019.10.011","article-title":"Acute kidney injury and electrolyte abnormalities after chimeric antigen receptor T-cell (CAR-T) therapy for diffuse large B-cell lymphoma","volume":"76","author":"Gupta","year":"2020","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"issue":"9967","key":"10.1016\/j.bulcan.2022.08.014_bib0335","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet Lond Engl"},{"issue":"5","key":"10.1016\/j.bulcan.2022.08.014_bib0340","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.bulcan.2022.08.014_bib0345","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bulcan.2022.08.014_bib0350","unstructured":"Jhaveri KD, Rosner MH. Chimeric Antigen Receptor T Cell Therapy and the Kidney: What the Nephrologist Needs to Know. Clin J Am Soc Nephrol [Internet]. 9 mars 2018 [cit\u00e9 4 nov 2021]; Disponible sur: https:\/\/cjasn.asnjournals.org\/content\/early\/2018\/03\/26\/CJN. 12871117."},{"issue":"1","key":"10.1016\/j.bulcan.2022.08.014_bib0355","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.kint.2019.07.022","article-title":"Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?","volume":"97","author":"Perazella","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.bulcan.2022.08.014_bib0360","doi-asserted-by":"crossref","unstructured":"Ratna Acharya, Biljana Horn, Xu Zeng, Kiran Upadhyay. Collapsing Focal Segmental Glomerulosclerosis and Acute Kidney Injury Associated With Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: A Case Report. Kidney Med [Internet]. 8 sept 2021 [cit\u00e9 5 avr 2022];3(6). Disponible sur: https:\/\/pubmed.ncbi.nlm.nih.gov\/34939018\/.","DOI":"10.1016\/j.xkme.2021.06.011"},{"issue":"5","key":"10.1016\/j.bulcan.2022.08.014_bib0365","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00467-006-0026-5","article-title":"A case of unfulfilled expectations. Cytokines in idiopathic minimal lesion nephrotic syndrome","volume":"21","author":"Araya","year":"2006","journal-title":"Pediatr Nephrol Berl Ger"},{"key":"10.1016\/j.bulcan.2022.08.014_bib0370","unstructured":"Interleukin-8 alters glomerular heparan sulfate glycosaminoglycan chain size and charge in rats - PubMed [Internet]. [cit\u00e9 9 avr 2022]. Disponible sur: https:\/\/pubmed.ncbi.nlm.nih.gov\/10775070\/."},{"issue":"1","key":"10.1016\/j.bulcan.2022.08.014_bib0375","first-page":"61","article-title":"Distribution of interleukin-6 in normal and diseased human kidney","volume":"65","author":"Fukatsu","year":"1991","journal-title":"Lab Investig J Tech Methods Pathol"},{"issue":"6","key":"10.1016\/j.bulcan.2022.08.014_bib0380","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1053\/j.ajkd.2014.10.012","article-title":"Acute kidney injury in adults with hemophagocytic lymphohistiocytosis","volume":"65","author":"Aulagnon","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"10","key":"10.1016\/j.bulcan.2022.08.014_bib0385","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1038\/sj.ki.5000352","article-title":"Nephrotic syndrome associated with hemophagocytic syndrome","volume":"69","author":"Thaunat","year":"2006","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.bulcan.2022.08.014_bib0390","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.xkme.2021.03.011","article-title":"Acute kidney injury following chimeric antigen receptor T-cell therapy for B-cell lymphoma in a kidney transplant recipient","volume":"3","author":"Melilli","year":"2021","journal-title":"Kidney Med"},{"key":"10.1016\/j.bulcan.2022.08.014_bib0395","unstructured":"Nattes T de, Camus V, Fran\u00e7ois A, Dallet G, Ferrand C, Guerrot D, Lemoine M, Morin F, Thieblemont C, Veresezan EL, Candon S, Latouche JB, Bertrand D. Kidney Transplant T Cell-Mediated Rejection Occurring After Anti-CD19 CAR T-Cell Therapy for Refractory Aggressive Burkitt-like Lymphoma With 11q Aberration: A Case Report. Am J Kidney Dis [Internet]. 27 ao\u00fbt 2021 [cit\u00e9 5 avr 2022];0(0). Disponible sur: https:\/\/www.ajkd.org\/article\/S0272-6386(21)00824-6\/fulltext."},{"issue":"1","key":"10.1016\/j.bulcan.2022.08.014_bib0400","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nrneph.2011.168","article-title":"International kidney and monoclonal gammopathy research group. The pathogenesis and diagnosis of acute kidney injury in multiple myeloma","volume":"8","author":"Hutchison","year":"2011","journal-title":"Nat Rev Nephrol"},{"issue":"18","key":"10.1016\/j.bulcan.2022.08.014_bib0405","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMra1613984","article-title":"Acute kidney injury in patients with cancer","volume":"376","author":"Rosner","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.bulcan.2022.08.014_bib0410","doi-asserted-by":"crossref","first-page":"395","DOI":"10.4103\/ijn.IJN_215_16","article-title":"Plasma cell infiltration of the kidney as a manifestation of myeloma: a report of three cases","volume":"27","author":"Kaur","year":"2017","journal-title":"Indian J Nephrol"},{"issue":"2","key":"10.1016\/j.bulcan.2022.08.014_bib0415","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1097\/HS9.0000000000000186","article-title":"CAR T cell toxicity: current management and future directions","volume":"3","author":"Y\u00e1\u00f1ez","year":"2019","journal-title":"HemaSphere"},{"key":"10.1016\/j.bulcan.2022.08.014_bib0420","doi-asserted-by":"crossref","first-page":"663201","DOI":"10.3389\/fimmu.2021.663201","article-title":"Reactions related to CAR-T cell therapy","volume":"12","author":"Miao","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.bulcan.2022.08.014_bib0425","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bulcan.2022.08.014_bib0430","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/cid\/ciy152","article-title":"Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with chimeric antigen receptor T cells","volume":"67","author":"Park","year":"2018","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"issue":"6","key":"10.1016\/j.bulcan.2022.08.014_bib0435","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1097\/MCC.0000000000000356","article-title":"Sepsis-induced acute kidney injury","volume":"22","author":"G\u00f3mez","year":"2016","journal-title":"Curr Opin Crit Care"},{"key":"10.1016\/j.bulcan.2022.08.014_bib0440","first-page":"3584","article-title":"Risk of hyponatremia and associated clinical characteristics in patients with acute lymphoblastic leukemia after CD19 targeted chimeric antigen receptor (CAR) T-cells","volume":"130","author":"Dixon","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bulcan.2022.08.014_bib0445","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/rheumatology\/ken402","article-title":"Cyclophosphamide-associated complications: we need to be aware of SIADH and central pontine myelinolysis","volume":"48","author":"Jayachandran","year":"2009","journal-title":"Rheumatol Oxf Engl"},{"issue":"17","key":"10.1016\/j.bulcan.2022.08.014_bib0450","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1002\/cncr.25306","article-title":"Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome","volume":"116","author":"Lahoti","year":"2010","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.bulcan.2022.08.014_bib0455","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA Approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome","volume":"23","author":"Le","year":"2018","journal-title":"The Oncologist"},{"issue":"9","key":"10.1016\/j.bulcan.2022.08.014_bib0460","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s00134-020-06193-1","article-title":"Acute life-threatening toxicity from CAR T-cell therapy","volume":"46","author":"Azoulay","year":"2020","journal-title":"Intensive Care Med"},{"issue":"2","key":"10.1016\/j.bulcan.2022.08.014_bib0465","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1603017","article-title":"Initiation strategies for renal-replacement therapy in the intensive care unit","volume":"375","author":"Gaudry","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.bulcan.2022.08.014_bib0470","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12943-019-1057-4","article-title":"Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity","volume":"18","author":"Yu","year":"2019","journal-title":"Mol Cancer"},{"issue":"6","key":"10.1016\/j.bulcan.2022.08.014_bib0475","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"13","key":"10.1016\/j.bulcan.2022.08.014_bib0480","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1182\/blood-2016-04-711903","article-title":"T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma","volume":"128","author":"Ali","year":"2016","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.bulcan.2022.08.014_bib0485","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2022.08.014_bib0490","doi-asserted-by":"crossref","first-page":"S336","DOI":"10.1016\/j.bbmt.2018.12.544","article-title":"Emerging trends in chimeric antigen receptor T-cell immunotherapy in adults from the vizient clinical database","volume":"25","author":"Harris","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3, Supplement","key":"10.1016\/j.bulcan.2022.08.014_bib0495","doi-asserted-by":"crossref","first-page":"S316","DOI":"10.1016\/j.bbmt.2019.12.398","article-title":"Quality and cost outcomes in chimeric antigen receptor T-cell immunotherapy in adult large B-cell cancer patients from the vizient clinical database","volume":"26","author":"Harris","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.bulcan.2022.08.014_bib0500","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/CJI.0000000000000284","article-title":"Radiation priming chimeric antigen receptor T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma with high tumor burden","volume":"43","author":"Qu","year":"2020","journal-title":"J Immunother"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455122003538?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455122003538?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T02:02:58Z","timestamp":1719712978000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455122003538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":50,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0007455122003538"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2022.08.014","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute kidney injury after CAR-T cell infusion","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2022.08.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}